Thus, the results of g3mclass data analyses show the accuracy of identifying breast cancer potentially sensitive to anti-HER2 therapy and the robustness of the software in making the correct classification without equivocal results in the test and independent query. Here, ERBB2 is linked to breast carcinoma.